Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | NAMPT | P43490 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1664423 | 0.90 | MAPT (0.64) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL1663271 | 0.86 | NPC1 (0.65) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL8770393 | 0.86 | MAPT (0.59) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL1666202 | 0.85 | MAPT (0.58) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL5184503 | 0.85 | KMT2A (0.75) | KMT2AUSP2MAPTALDH1A1CYP2C9 | |
| SCHEMBL11889815 | 0.83 | TDP1 (0.64) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL1663821 | 0.82 | MAPT (0.55) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL1664431 | 0.82 | MAPT (0.56) | KMT2AUSP2MAPTNAMPTALDH1A1 | |
| SCHEMBL8770705 | 0.80 | MAPT (0.86) | KMT2AMAPTNAMPTALDH1A1CYP2C19 | |
| SCHEMBL1664364 | 0.79 | HPGDS (0.59) | KMT2AUSP2MAPTNAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260414-B2 | Inhibitors of hepatitic C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8921372-B2 | Inhibitors of hepatitis C virus | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2635571-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | Theravance, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| CN-103189371-A | Novel hepatitis c virus inhibitors | THERAVANCE INC | 2013-07-03 | — | — | CN | disclosed |
| WO-2012061552-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061552-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071878-A1 | NOVEL INHIBITORS OF HEPATITIC C VIRUS | HAVCR2, SLC10A1, HDGF | KMT2A 4426/4885USP2 3225/4885MAPT 3876/4885 |
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | KMT2A 3825/4885USP2 3530/4885MAPT 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.